JMP Securities Maintains Market Outperform on Enanta Pharma, Lowers Price Target to $42
Portfolio Pulse from jenniferd'souza@benzinga.com
JMP Securities analyst Roy Buchanan maintains a Market Outperform rating on Enanta Pharma (NASDAQ:ENTA) but has lowered the price target from $65 to $42.
August 08, 2023 | 1:47 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Enanta Pharma's price target has been lowered from $65 to $42 by JMP Securities, though the Market Outperform rating is maintained.
The lowering of the price target for Enanta Pharma by JMP Securities indicates a potential decrease in the stock's value in the short term. However, the maintenance of the Market Outperform rating suggests that the company is still expected to perform well in the market relative to other stocks.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100